8p11 myeloproliferative syndrome: one case report and review of literature / 白血病·淋巴瘤

Objective To improve the recognition of the 8p11 myeloproliferative syndrome(EMS).Methods Here a case with EMS was reported and the medical literature on this topic were reviewed. Results The patient was definitely dignosed and was treated with DA regimen. Conclusion EMS is a rare hematologic malignancy with poor prognosis and short life span. The small molecule tyrosine kinase inhibitors may bring hope in the future for patient with EMS.

The development of novel tyrosine kinase inhibitors / 白血病·淋巴瘤

At the end of last century,the snlall-molecule selective kinase inhibitor,imatinib mesylate (IM),Was successfully exploited.This resulted in a revolutionary step in the treatment of chronic myeloid leukemia(CML).However,along with the expansion of its clinical application and the process,drug resistance Was commonly observed in patients, especially during accelerated or blast phases, and has become a significant therapeutic problem in clinical application.The problem has prompted the appearance of novel small molecule tyrosine kinase inhibitors,and its development is reviewed.